Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
Carisma has expanded its collaboration with Moderna to develop two chimeric antigen receptor macrophage (CAR-M) targets for autoimmune disease treatment.
Dr. James Wilson takes on roles in two new companies spun out of Penn’s Gene Therapy Program
James Wilson, MD, PhD, has left Penn after 33 years to take on leadership roles in two independent startups that he co-founded.
Penn Medicine and Parker Institute renew alliance to continue groundbreaking cancer immunotherapy research
The continued collaboration will support laboratory studies and clinical trials that leverage the science of cancer immunology.
Penn Medicine researchers use AI to uncover potential antibiotic compounds
This groundbreaking study, published in Cell, represents the largest antibiotic discovery effort to date, significantly accelerating the process of identification of candidate molecules.
Penn Engineering’s Professors Discuss Innovations Over Tea
Their “brewing” collaboration recently led to the development of a novel chip that uses light for vector-matrix multiplication.
Penn Researchers Study New Treatment Options for Brain Cancer Patients
A team of Penn researchers are exploring whether MRIs that measure the "temperature" of tumors could enhance treatment for glioblastoma, a deadly brain cancer.
EpiVario Awarded NIH Grant to Advance Research in Treatments for Cocaine Use Disorder
EpiVario is developing neuroepigenetic modulators to treat memory-related addiction and psychiatric disorders.
Ultragenyx Aims for FDA Approval for Sanfilippo Gene Therapy Based on Penn Technology
The drug relies on licensed foundational gene therapy technology created in the laboratory of Dr. James Wilson, MD, PhD.
Interius BioTherapeutics Receives Clearance to Begin Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
Interius intends to begin patient enrollment for the trial in the fourth quarter of 2024.
Development of RNA Therapeutics Targets Neurological Diseases
The collaboration combines Ascidian's RNA exon editing technology with Roche's expertise in CNS delivery to create novel treatments for hard-to-treat neurological conditions.